Key points are not available for this paper at this time.
You have accessJournal of UrologyProstate Cancer: Basic Research LNCaP, LNCaP (ShPrKD1; silenced PrKD1), C4-2 and C4-2 PrKD1 were used for various sets of experiment to determine the role of DNA damage in PrKD1 overexpression and silencing cells. These cells were treated with varying concentrations and durations of compound-10 treatment and Etoposide (30µM), total cell lysates were prepared using RIPA Lysis and Extraction Buffer, cytosolic and nuclear fractions of C4-2 and C4-2 PrKD1 cells separated. The animal experiments were carried out following the Institutional Animal Care and Use Committee (IACUC) approval. The aim was to determine the tolerability of compound-10 by mice and generate preliminary data on efficacy of compound-10 in modulating the α-catenin and PrKD1 expressions in inhibiting tumor progression. RESULTS: In silico analysis, confirmed loss of T120 phosphorylation allows the beta- and alpha-catenin uncoupling. Forced expression of PrKD1 expression in prostate cancer cells increased alpha-catenin protein levels and was associated with resistance to etoposide induced DNA damage. Down regulation of alpha-catenin abrogates the PrKD1 protective effect of DNA damage. The in vitro results were corroborated in vivo using mouse prostate cancer xenograft model by inhibition of PrKD1 kinase activity with Compound 10, a selective PrKD inhibitor, demonstrating decreased beta-catenin T120 phosphorylation and alpha-catenin levels. CONCLUSIONS: The study for the first time provides a mechanistic basis of the protective role of PrKD1 against DNA damage. The findings could be used for further understanding of DNA damage in prostate cancer and d siRNA α-Catenin for 48 hours alone and in combinations. Source of Funding: N/A © 2024 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 211Issue 5SMay 2024Page: e47 Advertisement Copyright & Permissions© 2024 by American Urological Association Education and Research, Inc.Metrics Author Information Sanjeev Shukla More articles by this author Mohammed Al-Toubat More articles by this author Samuel Serrano More articles by this author Teruko Osumi More articles by this author K.C. Balaji More articles by this author Expand All Advertisement PDF downloadLoading ...
Shukla et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: